• 27 years as a Hematologist/Medical Oncologist, 20 years of clinical practice experience, and
    3 years as a physician executive.


Physician Executive, Medical Affairs, FDA Label Approvals, Oncology Genomic Profiling, Global Management in Oncology Therapeutics and Cancer Molecular Diagnostics, Clinical Studies Oversight, KOL Relations, Specialties: Hematology, Oncology, Lung Cancer, Genitourinary Cancer, Hematological Malignancies (myeloma and bone marrow transplantation), Thrombosis and Hemostasis Diseases, Cardiovascular), Collaboration and Team-building, Advisory Boards.

MD from Tufts University Medical School. Authored/co-authored 5 publications and 7 abstracts and/or invited presentations.


Director, Medical Affairs, Foundation Medicine, Inc. (FMI)

Reported to CMO. Participated in Senior Management Team meetings to map out Medical Affairs strategy and organization. Created and led key cross-functional teams to build medical support of Marketing and Commercial teams. Developed External Speakers Bureau for educational-promotional presentations by fellow clinicians on comprehensive genomic profiling of cancer. Created and guided team to review, update, and standardize all external medical/commercial promotional presentations. Created and oversaw team of Oncology RN reviewers to generate Medicare appeals letters to demonstrate benefit of genomic profiling in various cancer disease states. Led cross-functional team to submit letters to NCCN Disease Guideline Panels for adoption of comprehensive genomic profiling in the management of lung cancer, carcinoma of unknown primary, and soft tissue sarcomas to support clinician reimbursement. Reviewed and voted on research proposals submitted by external investigators on clinical investigation in cancer genomics and therapeutics. Developed company process and team to coordinate all scientific presentations and publications presented by internal/external investigators to leverage impactful, relevant medical data.

Associate Medical Director, Global Medical Affairs, Takeda: The Millennium Oncology Company

Member of a high profile cross-functional team that generated two successful FDA label revisions for Velcade (bortezomib). Planned and led advisory boards with national/regional level myeloma and lymphoma KOLs to support marketing department’s development of strategies to help with transition to first oral proteasome inhibitor in development (ixazomib). Oversaw 216 studies initiated by external investigators on oncologic applications/ aspects of Velcade. Led the Investigator Initiated Studies Research Program IRC in reviewing all Letters of Intent (LOI) and Summaries of Proposed Research (SOPRs) and voted on proposals/amendments. Developed active relationship with NIH’s NCI/CTEP (Clinical Trials Evaluation Program) to manage and renew NCI CRADA for Velcade, and explored CRADA for other molecules in development (ixazomib). Revised internal guidance for IISR program. Worked closely with MSL team to manage external investigator and KOL relationships. Formed and led cross-functional team to coordinate multiple research projects including pre-clinical and clinical studies to examine the cardiac safety profile of current proteasome inhibitors. Created Cardio-Oncology Advisory panel, a network of national experts, to advise on cardiac safety of proteasome inhibitors. Advised Marketing leadership on medical necessity and patient care needs to help formulate and implement effective marketing strategies. Provided Medical Affairs representation and clinical guidance to lead Velcade PV officer at all Velcade PV meetings. Served as medical reviewer for high visibility cross-functional team that reviewed all promotional, Speakers Bureau, and sales training materials for US Velcade market.

Senior Staff Physician, Hematology-Oncology, Lahey Clinic

Physican Proprietor, Boston Hematology-Oncology

Staff Physician, Hematology-Oncology, The Cancer Center of Boston